Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors
“We are very honored to have Ann join our Board,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics. “Ann’s career experience, industry knowledge and leadership capabilities will be tremendous assets for our Board and management team.”
Dr. Hanham is a founding and managing partner of
“I am very excited to have the opportunity to work with TJ, his team and the Board as they continue their important work in developing NGS-based molecular profiling. I believe the company’s technology has the potential to revolutionize the diagnosis and delivery of targeted therapies,” stated Dr. Hanham.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed director and her expected benefits to us and the potential of our technology to affect the diagnosis and delivery of targeted therapies. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop new methods and/or technologies, to successfully develop and commercialize diagnostic products, including companion diagnostic products, and to successfully markets for our products. These and other factors are described in greater detail in our filings with the
Westwicke Partners Jamar IsmailPhone: 415-513-1282 Email: firstname.lastname@example.org TJ Johnson President / CEO HTG Molecular DiagnosticsPhone: 520-547-2827 x130 Email: email@example.com